Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
08:26am, Tuesday, 03'rd Jun 2025
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-bo
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
01:00pm, Monday, 02'nd Jun 2025
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
12:48pm, Monday, 02'nd Jun 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar
Sanofi-Blueprint deal is a bullish signal about biotech M&A
11:46am, Monday, 02'nd Jun 2025
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San
Sanofi Exercises License Extension Option to Nurix's STAT6 Program
07:00am, Monday, 02'nd Jun 2025
STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi
Sanofi doubles down on immunology with $9.1bn Blueprint deal
04:31am, Monday, 02'nd Jun 2025
Sanofi SA (ADR) (NYSE:SNY) is placing a major bet on rare immune disorders with its $9.1bn acquisition of US biotech firm Blueprint Medicines, part of a wider push to become a global leader in immuno
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
01:24am, Monday, 02'nd Jun 2025
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies s
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
01:22am, Monday, 02'nd Jun 2025
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
09:15am, Saturday, 31'st May 2025
Sanofi faces setbacks after itepekimab's Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Despite challenges, Sanofi is attractively valued, with my DCF anal
Itepekimab Failure A Setback For Sanofi And Regeneron
02:10pm, Friday, 30'th May 2025
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
11:21am, Friday, 30'th May 2025
Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.
Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials
03:19am, Friday, 30'th May 2025
Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.
